Australia approves Gilead's remdesivir for Covid-19 treatment
[BENGALURU] Australia has granted provisional approval to Gilead Sciences's remdesivir as the first treatment option for Covid-19 in the country, the Therapeutic Goods Administration (TGA) said on Friday.
The approval is for adults and adolescent patients with severe Covid-19 symptoms and have been hospitalised, the Australian regulator said.
Remdesivir has become the treatment of choice for many countries against severely ill Covid-19 patients after the intravenously-administered medicine helped shorten hospital recovery times in a clinical trial.
The Australian approval broadens the use of remdesivir around the world - the United States has cleared it for emergency use and the European Commission has conditionally approved the treatment.
It is also approved as a Covid-19 therapy in Japan, Taiwan, India, Singapore and the United Arab Emirates.
Australia has been struggling to contain a Covid-19 outbreak in the country's second most populous city and on Friday said it would halve the number of citizens allowed to return home from overseas each week.
SEE ALSO
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
Philippines’ Recto sees rate-cut delay risk if peso sinks to 59
Ecuador president declares state of emergency over energy crisis
US Senate has agreement on Fisa reauthorisation, will vote on Friday night, Schumer says
US expects to finalise new Aukus trade exemptions in next 120 days
IMF concerned about debt, fiscal challenges facing low-income countries
Bank of Japan’s Ueda says ‘very likely’ to hike rates if inflation keeps rising